IP Library Granted Patent US 12,594,230
Granted Patent B2
US 12,594,230 · App. 18/004,553 · Granted Apr 7, 2026

Sphingolipid containing salicylic acid derivative and composition comprising same

Inventors: Ara Kim (Yongin-si, KR); Kwanhyoung Lee (Yongin-si, KR); Daebang Seo (Yongin-si, KR)
Assignee: Croda Korea Ltd
A61K8/68A61Q5/00C07C235/60A61K2800/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,230
App. No.
18/004,553
Granted
Apr 7, 2026
Kind
B2
Abstract

A composition for skin application and uses thereof are disclosed. The composition includes a sphingolipid containing a salicylic acid derivative as an active ingredient. The composition including a sphingolipid containing a salicylic acid derivative may exhibit, when applied to the scalp, an effect of alleviating scalp erythema, an effect of increasing the amount of moisture in the scalp, an effect of inhibiting scalp sebum secretion, an effect of inhibiting scalp itchiness, and the like.

Claims (20)

1 . A sphingolipid having a salicylic acid derivative and represented by Chemical Formula 1:

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

R1 is C(H)OH—CH 2 ;

R2 is C 13 H 27 ;

R3 is H;

R4 is C═OR5; and

R5 is CH 3 .

2 . A composition for application to the skin, the composition comprising the sphingolipid of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

3 . The composition of claim 2 , wherein the sphingolipid is present in an amount of 0.0001 to 55 wt % relative to the total weight of the composition.

4 . The composition of claim 2 , wherein the composition has a pH of 3 to 9.

5 . The composition of claim 2 , further comprising at least one of phytosphingosine, sphingosine, and sphinganine.

6 . The composition of claim 2 , further comprising at least one of ceramide 1 (EOS), ceramide 2 (NS), ceramide 3 (NP), ceramide 4 (EOH), ceramide 5 (AS), ceramide 6 (NH), ceramide 7 (AP), ceramide 8 (AH), and ceramide 9 (EOP).

7 . The composition of claim 2 , wherein the composition comprises no surfactant.

8 . The composition of claim 2 , wherein the composition is capable of scalp improvement.

9 . The composition of claim 8 , wherein the scalp improvement is at least one selected from the group consisting of alleviating scalp inflammation, relieving scalp itching, improving scalp moisturizing, soothing scalp, inhibiting dandruff bacterial growth, and preventing hair loss.

10 . The composition of claim 2 , wherein the composition is formulated into at least one selected from the group consisting of a cream, an essence, a lotion, a toner, a gel, an ointment, an oil, and a tonic.

11 . A cosmetic composition comprising the sphingolipid of claim 1 and one or more water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, natural extracts, waxes, oils, detergents, surfactants, colorants, and flavoring agents.

12 . The composition of claim 11 , wherein the composition is capable of anti-aging.

13 . An externally applied composition capable of relieving itching comprising the sphingolipid of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Nov 30, 2023
From: SOLUS BIOTECH CO., LTD.
To: CRODA KOREA LTD
Reel/Frame 065721/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: KIM, ARA; LEE, KWANHYOUNG; SEO, DAEBANG
To: SOLUS BIOTECH CO., LTD.
Reel/Frame 062298/0519 →
Priority Claims (1)
KR 10-2020-0084867 · Jul 9, 2020 · national
Continuity (1)
Related Publication 20240252414A1 · Aug 1, 2024
References Cited (14)
US 20050245464A1 · Yedgar · 2005 [cited by examiner]
US 20070003509A1 · Farwick et al. · 2007 [cited by applicant]
US 20080249073A1 · Farwick et al. · 2008 [cited by applicant]
US 20090010968A1 · Allart et al. · 2009 [cited by applicant]
US 20140170092A1 · Farwick · 2014 [cited by examiner]
KR 1020000070718A · 2000 [cited by applicant]
KR 1020130004448A · 2013 [cited by applicant]
KR 1020190114864A · 2019 [cited by applicant]
WO 2019173584A1 · 2019 [cited by applicant]
National Center for Biotechnology Information. “PubChem Compound Summary for CID 2244, Aspirin” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin. Accessed Oct. 28, 2025. [cited by examiner]
Office Action dated Feb. 15, 2023, issued in Korean Application No. 10-2020-0084867. [cited by applicant]
S. Naumann et al., “Penetration Studies of an Extremely Lipophilic Active Model Substance from an Oil-in-Water Emulsion: Influence of the Lipophilicity of the Formulation in Human Skin—Part 2”, Skin Pharmacology and Phy… [cited by applicant]
International Search Report for PCT/KR2020/019241 dated Apr. 23, 2021. [cited by applicant]
Office Action (The Third Office Action) issued Jul. 24, 2024, by the State Intellectual Property Office of People's Republic of China in corresponding Chinese Patent Application No. 202080103861.6 and an English transla… [cited by applicant]